Biomatics Capital
  • Portfolio
  • Team
  • News
  • Contact
  • Investor Portal
Select Page

Denali

PUBLIC | NASDAQ:DNLI
Focus on neurodegenerative diseases such as Parkinson’s and Alzheimer’s
http://www.denalitherapeutics.com/

Press Releases

Denali Therapeutics Announces First Patient Dosed in Phase 1B Study of DNL201 for Parkinson’s Disease

Dec 10, 2018

Next Entries »

Press Coverage

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

© Copyright 2025 Biomatics Capital